一项研究发现,在具有BRCA/HRR基因突变的男子中,niraparib会减慢前列腺癌的速率。 A study finds niraparib slows advanced prostate cancer in men with BRCA/HRR gene mutations.

伦敦大学学院领导的一项全球研究发现,在标准治疗中加上药物硝酸盐会大大减缓有特定基因突变的男子前列腺癌的蔓延,特别是在BRCA1/BRCA2和其他同族重组修复基因中。 A global study led by University College London finds that adding the drug niraparib to standard treatment significantly slows prostate cancer progression in men with specific genetic mutations, particularly in BRCA1/BRCA2 and other homologous recombination repair (HRR) genes. 在696名患前列腺癌前列腺癌的男子中,这一结合总体上降低了37%的累进风险,在BRCA突变的男子中降低了48%的累进风险。 Among 696 men with advanced prostate cancer, the combination reduced progression risk by 37% overall and 48% in those with BRCA mutations. 虽然生存数据仍然不成熟,但结果有利于两者的结合。 While survival data remain immature, results favor the combination. 研究人员支持在诊断时进行更广泛的基因检测,以确定哪些病人可能受益最多,专家们建议讨论治疗对符合条件的病人的副作用。 Researchers support wider genetic testing at diagnosis to identify patients who may benefit most, and experts recommend discussing the treatment’s benefits against side effects for eligible patients. 研究报告在《自然医学》上发表。 The study was published in Nature Medicine.